explore -WSS

explore

author：leisure time 2025-09-05 08:06:19 - browse：6

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

hotspot

WSS

California’s proposed $25 per hour health care minimum wage

Gain of function research would be limited under House proposal

FDA's Woodcock to retire early next year

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Surge of respiratory disease in China has likely explanation

Surge of respiratory disease in China has likely explanation

hotspot

explore

hotspot

In Memoriam: Notable people who died in 2023

NIH fellows want a pay raise. Will that mean less money for grants?

Novavax promises a turnaround & Lilly roils the obesity market

Wegovy, Zepbound and weight loss drugs that preserve muscle

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

N.Y. state detects polio case, first in the U.S. since 2013

Medical records are filled with copy

World's first CRISPR

Moonlake's readout produced a cash windfall. Risks remain

Wegovy, Zepbound and weight loss drugs that preserve muscle

entertainment

Why 40% Americans with Parkinson’s don’t see a neurologist

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Living with Fabry disease, a condition that causes chronic pain

Anthos stroke drug appears safer than common blood thinner

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

focus

hotspot

hotspot

knowledge